Sellas Life Sciences Group Inc (SLS)

Jul 22, 2025

What analysts say about SELLAS Life Sciences Group Inc. stockDynamic capital growth - Autocar Professional

Jul 22, 2025

Jul 22, 2025

What drives SELLAS Life Sciences Group Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is SELLAS Life Sciences Group Inc. a good long term investmentFree Bull & Bear Market Updates - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

SELLAS Life Sciences Group Inc. Stock Analysis and ForecastFree Advanced Stock Screener Access - jammulinksnews.com

Jul 22, 2025

Jul 20, 2025

What makes SELLAS Life Sciences Group Inc. stock attractive to long term investorsMomentum Swing Watchlist - beatles.ru

Jul 20, 2025

Jul 18, 2025

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Expected to Rise, Maxim Group Analyst Says - Defense World

Jul 18, 2025

Jul 16, 2025

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities - Finansavisen

Jul 16, 2025

Jul 16, 2025

Sellas Life Sciences shares fall 1.58% premarket after meeting primary endpoints in Phase 2 trial. - AInvest

Jul 16, 2025

Jul 16, 2025

SELLAS Meets All Primary Endpoints in Phase 2 Trial of - GlobeNewswire

Jul 16, 2025

Jul 15, 2025

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success - insights.citeline.com

Jul 15, 2025

Jul 15, 2025

What makes SELLAS Life Sciences Group Inc. stock price move sharplyReal Time Breakout Tracking - Newser

Jul 15, 2025

Jul 15, 2025

How SELLAS Life Sciences Group Inc. stock performs during market volatilityHigh Yield Opportunities - Newser

Jul 15, 2025

Jul 15, 2025

Sellas Flat on Trial Success - Baystreet.ca

Jul 15, 2025

Jul 15, 2025

Sellas Life Sciences Meets Primary Endpoints in Mid-Stage SLS009 Trial - MarketScreener

Jul 15, 2025

Jul 15, 2025

SELLAS gains on mid-stage trial win for leukemia drug (SLS) - Seeking Alpha

Jul 15, 2025

Jul 15, 2025

SELLAS' Phase 2 Study Of SLS009 In Acute Myeloid Leukemia Meets All Primary Goals - Nasdaq

Jul 15, 2025

Jul 15, 2025

Why SELLAS Life Sciences Group Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser

Jul 15, 2025

Jul 15, 2025

SELLAS Life Sciences Group Reports Positive Phase 2 Trial Results for SLS009 in Relapsed/Refractory Acute Myeloid Leukemia - Nasdaq

Jul 15, 2025

Jul 15, 2025

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study - The Manila Times

Jul 15, 2025

Jul 10, 2025

SELLAS Life Sciences Soars 14.21% on Key Appointment - AInvest

Jul 10, 2025

Jul 09, 2025

SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Market Movement, Down and Up - investchronicle.com

Jul 09, 2025

Jul 09, 2025

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.7% – Here’s What Happened - Defense World

Jul 09, 2025

Jul 07, 2025

SELLAS Life Sciences adds cancer research expert to scientific board By Investing.com - Investing.com Nigeria

Jul 07, 2025

Jul 07, 2025

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board - citybiz

Jul 07, 2025

Jul 07, 2025

SELLAS Life Sciences adds cancer research expert to scientific board - Investing.com

Jul 07, 2025

Jul 07, 2025

Cancer Research Leader from MD Anderson Strengthens SELLAS Scientific Board Ahead of Key Milestones - Stock Titan

Jul 07, 2025

Jun 30, 2025

SELLAS Life Sciences Group, Inc.(NasdaqCM: SLS) added to Russell 2500 Growth Index - MarketScreener

Jun 30, 2025